ERBB2 and cancer: As the cardiotoxic effects of DOX remained a key limiting factor, targeted therapy with the use of this anthracycline and guiding vector Tmab might limit the damage to healthy tissues, well as improve the clinical outcomes of patients suffering from HER2+ cancers.